drugset / Trial / NCT03799510

Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children

NCT03799510

RandomizedParallel-groupOpen-labelPrevention

Summary

The clinical trial phase 2b is designed to assess the safety and the specific immune response of the active ingredient (protein + adjuvant) in healthy and then in infected school children from 8 to 11 years of age with intestinal and/or urinary schistosomiasis, living in the Valley of the Senegal River, a highly endemic area for schistosomiasis.

Timeline

Start
2018-12-13
Primary completion
2019-07-01
Completion
2019-08-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject rSm14 Protein / enzyme biologic 50 ug Intramuscular
Background GLA-SE Other / unclassified 2.5 ug Intramuscular

Indications